Dogwood Therapeutics DWTX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's change in accrued liabilities?
- Dogwood Therapeutics (DWTX) reported change in accrued liabilities of $187.83K in Q1 2026.
- How has Dogwood Therapeutics's change in accrued liabilities changed year-over-year?
- Dogwood Therapeutics's change in accrued liabilities increased by 202.4% year-over-year, from -$183.35K to $187.83K.
- What is the long-term trend for Dogwood Therapeutics's change in accrued liabilities?
- Over 3 years (2022 to 2025), Dogwood Therapeutics's change in accrued liabilities has grown at a 10.4% compound annual growth rate (CAGR), from -$451.66K to $608.29K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.